Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2021-12-16 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物公司章程（2021年12月）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 杭州安旭生物科技股份有限公司 (Assure Tech (HangZhou) Co., Ltd.). It includes chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, internal audit, appointment of accounting firms, notices and announcements, mergers, capital changes, dissolution, liquidation, and amendments to the articles. The content is focused on governance structure, shareholder rights, meeting procedures, voting rules, and company management rules. There is no indication of financial statements, audit reports, earnings data, or announcements of voting results. Instead, it is a governance document detailing the internal rules and structure of the company. Therefore, the document best fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full governance document, not just an announcement or summary.
2021-12-16 Chinese
安旭生物关于公司使用募集资金置换预先投入募投项目及支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Hangzhou Anxu Biotechnology Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects and to pay issuance fees. It details the approval by the board and supervisory committee, references regulatory approvals, and includes independent opinions and audit reports related to the use of funds. The document is focused on the company's capital management and financing activities, specifically the replacement of self-raised funds with raised funds from a public offering. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a simple announcement of a report publication but a substantive disclosure about capital use. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4374 characters, which is substantive enough to be a full announcement rather than a brief notice.
2021-12-16 Chinese
安旭生物关于变更公司注册资本、公司类型、修订《公司章程》并办理工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding changes in the company's registered capital, company type, and amendments to the Articles of Association. It details the approval from the China Securities Regulatory Commission for the company's initial public offering, the increase in registered capital and shares, the company's listing on the Shanghai Stock Exchange Science and Technology Innovation Board, and the corresponding amendments to the Articles of Association. The document is a formal announcement of these corporate changes and regulatory approvals, not a full financial report or detailed filing. It is relatively short (1561 characters) and serves as a public notice of corporate structural changes and regulatory compliance rather than a detailed report or financial statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-16 Chinese
信永中和会计师事务所（特殊普通合伙）关于安旭生物以自筹资金预先投入募投项目及支付发行费用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a verification report (鉴证报告) issued by an accounting firm (ShineWing) regarding the use of self-raised funds to pre-invest in fundraising projects and pay issuance expenses by Hangzhou Anxu Biotechnology Co., Ltd. It references regulatory guidelines for fundraising management and usage, and includes detailed financial figures about the fundraising and pre-investment amounts. The report is a standalone audit-type verification focused on a specific aspect of fundraising and fund usage, not a full annual or interim financial report. It is not a general annual report, earnings release, or management discussion. The document is a specialized assurance report on compliance with fundraising regulations and fund usage, fitting the definition of an Audit Report / Information (AR). The document length is about 4791 characters, which is sufficient for a detailed audit report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2021
2021-12-16 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司使用募集资金置换预先投入募投项目及支付发行费用的自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Minsheng Securities regarding Hangzhou Anxu Biotechnology Co., Ltd.'s use of raised funds to replace self-raised funds previously invested in projects and payment of issuance expenses. It references regulatory approvals, fundraising details, investment projects, and audit opinions. The document is a formal verification or audit opinion related to the use of funds raised in an IPO and compliance with relevant laws and regulations. It does not contain a full annual or interim financial report, earnings release, or other financial statements. It is a standalone audit or verification report on a specific financial compliance matter, consistent with an Audit Report / Information filing. FY 2021
2021-12-16 Chinese
安旭生物第一届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Hangzhou Anxu Biotech Co., Ltd. It details the meeting date, attendance, and the approval of a proposal regarding the use of raised funds to replace self-raised funds for investment projects and issuance expenses. The document references compliance with regulatory guidelines and confirms the legality and validity of the meeting and resolution. It does not contain financial statements or detailed financial data but is an official announcement of a board-related decision. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2021-12-16 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.